The future of epigenetic therapy: CPI-0610 for the treatment of myeloidfibrosis

Abstract

Jigar Raythatha speaks to Lucy Chard, Commissioning Editor: Jigar Raythatha has spent nearly 20 years in the biotechnology industry in a variety of business functions. He rejoined Constellation in March 2017 as the company's Chief Executive Officer, from Jounce Therapeutics, where he held the role of the Chief Business Officer. At Jounce, Jigar was the first employee and helped build the company from its inception to a 100-person, publicly traded research and development organization. Previously, he served as the head of the corporate development at Constellation, where he led business development, strategy, and program and alliance management functions. Prior to his first stint at Constellation, Jigar worked with Red Abbey Venture Partners. Earlier in his career, Jigar held roles of increasing responsibility at Biogen and A.T. Kearney. He earned an MBA from Columbia University and a BA in biochemistry and economics from Rutgers University.

Keywords: BET; CPI-0610; EZH2 pathway; clinical trials; epigenetics; epigenomics; myeloidfibrosis; prostate cancer; therapeutics.